The FDA has accepted Merck's (NYSE:MRK) supplemental New Drug Application with priority review for its drug Welireg, also known as belzutifan, for the treatment of a rare type of adrenal gland ...

Acceptance based on objective response rate data from the Phase 2 LITESPARK-015 trial evaluating WELIREG in certain patients with advanced PPGL If approved, WELIREG would be the only available therapy ...

Orders for U.S. manufactured goods fell in November, reversing course after an October increase. Manufacturers’ new orders totaled $586.1 billion in November, down 0.4% from $588.2 billion in ...

Nondurable goods orders grew 0.4%. Other indicators from the report on factory activity showed a more positive trend. Shipments grew by 0.1% to $586.3 billion, ending a three-month stretch of ...

or metastatic pheochromocytoma and paraganglioma (PPGL). The sNDA is based on objective response rate (ORR) and duration of response (DOR) data from the Phase II LITESPARK-015 trial, which will be ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

At close: January 17 at 4:12:21 PM GMT+7 ...